Genenta Science S.p.A. Unsponsored ADR GNTA
0.69
0.02
2.99%
as of 25 Sep
- Market cap
- $32.4M
- P/E
- —
Follow GNTA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
14.16 | 6.89 | 12.25 | 14.53 | 34.15 | 7.09 | 8.29 | — |
Net Debt/EBITDA |
3.12 | 1.30 | 1.61 | 2.70 | 6.55 | 2.77 | 4.37 | — |
Debt/Assets |
23.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.35 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.05 | 0.70 | 0.96 | 0.88 | 1.26 | 1.08 | 0.54 | — |
Capex/Depreciation |
(0.27) | (0.10) | (0.32) | (4.38) | (1.84) | (10.82) | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (38.65%) | (54.13%) | (45.90%) | (22.68%) | (20.67%) | (33.21%) | (25.93%) | — | |
| (28.35%) | (47.95%) | (42.43%) | (21.63%) | (19.43%) | (29.06%) | (42.95%) | — | |
ROIC |
(318.86%) | 0.00% | (442.67%) | (513.85%) | (219.27%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(23.42%) | (71.78%) | (59.40%) | (28.59%) | (14.69%) | (39.33%) | (25.31%) | — |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.39) | (0.37) | (0.67) | (0.43) | (0.55) | (0.48) | (0.15) | — |
Cash per Share |
1.62 | 0.75 | 1.12 | 1.72 | 2.92 | 1.22 | 1.25 | — |
Shareholders Equity per Share |
1.25 | 0.74 | 1.21 | 1.80 | 3.05 | 1.19 | 1.17 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.25 | 0.74 | 1.21 | 1.80 | 3.05 | 1.19 | 1.17 | — |
Free Cash Flow |
(7.78) | (6.76) | (12.14) | (7.84) | (8.24) | (6.93) | (2.79) | — |
Working Capital |
31.52 | 13.39 | 21.13 | 31.12 | 44.51 | 16.22 | 20.33 | — |
Capital Expenditures |
(0.01) | 0.00 | (0.01) | (0.03) | (0.01) | (0.02) | — | — |
Net Current Asset Value |
22.55 | 13.14 | 20.93 | 31.00 | 44.48 | 16.20 | 20.32 | — |
| Other line items | ||||||||
Quick Ratio |
13.29 | 6.03 | 10.82 | 13.65 | 32.81 | 6.63 | 8.18 | — |
Depreciation/Fixed assets |
1.25 | 1.04 | 0.51 | 0.06 | 0.21 | 0.10 | — | — |
Cash ROIC |
(11.96%) | (24.98%) | (28.79%) | (12.36%) | (9.17%) | (19.80%) | (6.37%) | — |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.39) | (0.37) | (0.67) | (0.43) | (0.55) | (0.47) | (0.15) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 0.69 | 0.51 | 0.28 | 0.28 | — |
Average Payables |
1.29 | 0.52 | 0.88 | 0.74 | 0.43 | — | — | — |
Average Assets |
26.06 | 20.11 | 29.71 | 41.29 | 33.67 | 21.98 | 11.98 | — |
Average Common Equity |
19.12 | 17.82 | 27.46 | 39.39 | 31.64 | 19.23 | 19.85 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates